Squarepoint Ops LLC Increases Stock Position in Certara, Inc. (NASDAQ:CERT)

Squarepoint Ops LLC increased its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 62.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,433 shares of the company's stock after acquiring an additional 36,386 shares during the period. Squarepoint Ops LLC owned about 0.06% of Certara worth $1,006,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of CERT. Blue Trust Inc. raised its stake in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares during the period. KBC Group NV raised its position in Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company's stock worth $85,000 after acquiring an additional 3,125 shares during the period. Choreo LLC boosted its stake in Certara by 25.0% in the fourth quarter. Choreo LLC now owns 50,582 shares of the company's stock valued at $533,000 after acquiring an additional 10,118 shares during the last quarter. Moloney Securities Asset Management LLC bought a new position in shares of Certara during the 4th quarter valued at approximately $128,000. Finally, Summit Trail Advisors LLC purchased a new stake in shares of Certara during the 4th quarter worth approximately $138,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Price Performance

Shares of Certara stock traded up $0.49 on Wednesday, reaching $11.95. The stock had a trading volume of 1,459,982 shares, compared to its average volume of 1,351,792. The business's 50 day moving average is $11.95 and its two-hundred day moving average is $11.80. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.76. The company has a market cap of $1.94 billion, a P/E ratio of -59.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same quarter in the prior year, the firm posted $0.10 EPS. Certara's revenue was up 9.7% on a year-over-year basis. As a group, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Stephens reissued an "overweight" rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. KeyCorp upped their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. William Blair reiterated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Finally, Robert W. Baird upped their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.67.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.